- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01637168
Comparison of the Panax Ginseng + Associations to Ginkgo Biloba in the Treatment of Cognitive Function Disorders
Clinical Phase III, Randomized, Double-blind, Prospective Study, for Efficacy and Safety Evaluation of Panax Ginseng + Associations Compared to Ginkgo Biloba in Symptomatic Cognitive Function Disorder Treatment.
The purpose of this study is to evaluate the efficacy and safety of two different drugs in the treatment of patients diagnosed with memory difficulties and a decline in cognitive function.
This is a parallel distribution: a group of patients will be treated with a combination Panax Ginseng + Ginkgo Biloba + multivitamin + Polyminerals (EMS), and another group with Ginkgo Biloba (Tebonin ®).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
STUDY DESIGN:
- multicenter, phase III, double-blind, randomized entry of patients, prospective and comparative
- The duration of the study: 60 days
- 3 visits (days 1, 30 and 60)
- Evaluate the effectiveness of the association
- Evaluate the safety of the combination
- Adverse events evaluation
Study Type
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
São Paulo
-
Cotia, São Paulo, Brazil, 06710-670
- Cliníca Dr. Felício Savioli
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients of any race, sex, aged 18-60 years;
- Patients presenting two or more symptoms associated with disorders of cognitive function such as memory impairment, poor concentration, depressed mood, decreased mental capacity, provided they score value is below 24 in the evaluation of the psychometric test (Mini Test-mental and WMS-R Logical Memory);
- Consent of the patient (Signature of the IC);
- Patients are able to read and write;
- "Washout" of at least two weeks of the start of the study, in case of use of multivitamins or any other medication for symptomatic treatment of disorders of cognitive function.
- Women of childbearing potential must submit βHCG negative serum;
- Patients are able to understand and carry out the study procedures;
Exclusion Criteria:
- Patients with hypersensitivity to the components of the formula;
- Patients who are making use of levodopa or salicylates;
- Routine use of medications that alter cognitive functions such as barbiturates, anticonvulsants, benzodiazepines, neuroleptics, alcohol and illicit drugs;
- Pregnant or lactating women;
- Participation in another clinical trial with investigational medication in the last 3 months;
- Patients with prior knowledge of infectious disease;
- Patients who are taking other multivitamins or any other medications for the symptomatic treatment of disorders of cognitive function, at least two weeks prior to study initiation.
- Patients with organic dementias such as Alzheimer's, Pick's disease, Creutzfeldt-Jacob Disease, Huntington's, Parkinson's disease, dementia caused by human immunodeficiency virus (HIV), hypothyroidism, vascular dementia (arteriosclerotic dementia), dementia senile among others;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Test Group
Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin - 1 tablet, 2 times a day (12/12 hours).
|
A tablet, 2 times daily (12/12 hours).
|
Active Comparator: Comparator Group
Ginkgo Biloba (Tebonin ®) - 1 tablet, 2 times a day (12/12 hours).
|
A tablet, 2 times daily (12/12 hours).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Study to evaluate the efficacy and safety of the association Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamins compared to Ginkgo Biloba (Tebonin ®) for the symptomatic treatment of disorders of cognitive function.
Time Frame: 60 days
|
To evaluate the efficacy of the association between Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin to treat patients with disorders of cognitive function compared to treatment with the drug Ginkgo Biloba (Tebonin ®) The assessment of effectiveness will be determined by statistical evaluation of the scores of responses related to quality of life questionnaires and psychometric tests (Mini-Mental Test and Test of Logical Memory WMS-R). |
60 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Study to evaluate the efficacy and safety of the association Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamins compared to Ginkgo Biloba (Tebonin ®) for the symptomatic treatment of disorders of cognitive function.
Time Frame: 60 days
|
To evaluate the safety of the association between Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin to treat patients with disorders of cognitive function compared to treatment with the drug Ginkgo Biloba (Tebonin ®). The safety of the medication to be prescribed by the observation of adverse events and related to the study medication. Analysis of safety tests (biochemical profile, complete blood count, blood glucose, cholesterol and uric acid) requested at visit 1 and 2. |
60 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Felício MD Savioli Neto, Cliníca Dr. Felício Savioli
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GGKEMS0910
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Memory Deficit
-
University of Texas Southwestern Medical CenterTerminatedMood | Memory DeficitUnited States
-
University of PennsylvaniaNational Institutes of Health (NIH)TerminatedAttention Deficit Hyperactivity Disorder | Attention Deficit Disorder | Working MemoryUnited States
-
University Hospital, GrenobleCompleted
-
University of WyomingActive, not recruitingAttention Deficit Hyperactivity Disorder | Working Memory | Change in Sustained Attention | Effects of; ExertionUnited States
-
University of WyomingRecruitingAttention Deficit Hyperactivity Disorder | Mood | Working Memory | Stimulant Use | Change in Sustained AttentionUnited States
-
Stony Brook UniversityNational Center for Neuromodulation for RehabilitationTerminatedStroke | Cognitive Impairment | Cognitive Deficit | Short-Term Memory ImpairmentUnited States
-
Kutahya Health Sciences UniversityCompletedWorking Memory | The Working Memory QuestionnaireTurkey
-
Prof. Dominique de Quervain, MDClinical Trial Unit, University Hospital Basel, SwitzerlandCompletedMemory, Short-Term | Memory, Long-TermSwitzerland
-
Erasmus Medical CenterEnrolling by invitationCOVID-19 | Cognitive Impairment | Memory Disorders | Memory Impairment | Attention Impaired | Memory Loss | Cognition Disorder | Attention DeficitNetherlands
-
Memorial Sloan Kettering Cancer CenterCompletedMemory Losses | Amnesia-Memory LossUnited States
Clinical Trials on Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin
-
University of PretoriaWithdrawnDietary Supplements | Bleeding Tendency; Due to Coagulation Defect
-
National Institutes of Health Clinical Center (CC)Completed
-
Sunway UniversityCompletedBlood Pressure | CognitionMalaysia
-
Amen Clinics, Inc.CompletedTraumatic Brain InjuryUnited States